The FDA on Sept. 25 approved Juvmo (tavapadon), a once-daily pill from AbbVie, to treat Parkinson's disease in adults, according to the agency's 2026 list of novel drug approvals. Nausea, dizziness, and headache were among the most common side effects reported in clinical trials.
AbbVie did not disclose a price or launch date, Reuters reported. According to the same report, Citi analysts had expected a third-quarter 2026 launch, with gradual uptake as Medicare coverage is negotiated.